
De-identification of clinical trial data at Novo Nordisk A/S to enable secondary use of anonymized* data for research

In order to facilitate the use of data from our clinical research in further scientific investigations, Novo Nordisk has established a new system for sharing of data with external researchers in response to legitimate scientific requests. Via this system external researchers can submit their requests for access to anonymised* datasets from Novo Nordisk sponsored clinical trials.



In case of approval, Novo Nordisk provides t de-identified trial data to protect patient anonymity together with the redacted Clinical Study Report, thus enabling the researcher to complete the proposed analysis.

Secondary use of clinical data




- Custom SAS de-identification and risk assessment tools
- Single-sponsor highly secured portal
- Metadata controlled de-identification and documentation
- Specified rules for column and row de-identification: randomization, generalization, computation, suppression, masking, ... etc.
- Risk assessment
- Documentation







European Federation of Pharmaceutical Industries and Associations













^{*} Anonymised subject data is irreversible de-identified data (where the key, randomization seed and the link between original data are deleted to prevent traceability to subjects) of already anonymous subject data.